Expanding the Use of CAR T Therapy With shRNA

Video

The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.

Celyad Oncology is targeting cancers with a number of allogeneic CAR T-cell therapies. Their lead program, CYAD-211, is currently being evaluated in the phase 1 IMMUNICY trial (NCT04613557).

Celyad presented positive interim data at the European Hematology Association (EHA) 2021 Congress in June 2021 from IMMUNICY that showed dose-dependent engraftment up to dose level 3 of 300 x 106 cells per infusion. 

The company reported that no graft-versus-host disease, dose-limiting toxicities, or CAR T-cell related encephalopathy syndromes have occurred to date. A partial response was seen in 2 of the 5 evaluable patients. CYAD-211 cells were detected by polymerase chain reaction-based methods in all 6 patients with evidence of a dose-dependent increase in cell engraftment.

GeneTherapyLive spoke with Filippo Petti, chief executive officer and chief financial officer, and Charles Morris, MBBS, chief medical officer, Celyad Oncology, about the company's future plans and upcoming research. They also discussed potential future opportunities for their short hairpin RNA platform.

REFERENCE
Celyad Oncology presents updates on allogeneic CAR T clinical candidates and shRNA-based preclinical concepts at research & development day. News release. Celyad Oncology. July 20, 2021. https://www.businesswire.com/news/home/20210720005854/en/Celyad-Oncology-Presents-Updates-on-Allogeneic-CAR-T-Clinical-Candidates-and-shRNA-based-Preclinical-Concepts-at-Research-Development-Day
Recent Videos
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
Related Content
© 2025 MJH Life Sciences

All rights reserved.